International Congress of Transplantation Society forum for cutting-edge research results

July 10, 2002

New findings in clinical and basic science transplantation research will be presented at the XIX International Congress of The Transplantation Society August 25 - 30, among them results of a study that treated diabetic children with a combination of cells from a pig's pancreas and testes, and findings from three separate studies with a common goal in mind: to wean organ transplant patients off all anti-rejection drugs less than one year after transplantation, defying the tenet that such drugs are required for life.

The congress will take place at the Westin Diplomat Resort and Spa in Hollywood, Fla., located on the coast between Miami and Ft. Lauderdale. A staffed press room will be on site, and press briefings and media availabilities will be held each day.

As with other congresses, a familiar theme of discussion will be the worldwide organ donor shortage crisis - in some countries with active transplant centers there are less than 10 or 20 cadaveric organ donors a year- but at this congress, much of the discussion also will focus on the repercussions of the organ shortage. Thousands of patients continue to die each year awaiting transplantation, and in response, surgeons are beginning to rely more on living donors. In the United States alone, the numbers have increased more than 12 percent from 2000. But in some parts of the world, these numbers are part and parcel to a growing black market for organs from living donors. The practice of buying and selling organs is of particular concern to The Transplantation Society, the field's only international society, with more than 3,000 members from 65 countries, including those where such black markets exist. Among the many research studies to be presented at the congress and featured in the press room are:

• A team from Mexico and Canada will report that some diabetic children were able to stop daily insulin injections after receiving infusions of pig cells, which were given without immunosuppression, while Italian researchers will report that transplanting human pancreatic islets cells can reduce the complications of diabetes 10 years after transplantation. Additional studies focusing on cell transplantation for the treatment of diabetes include those examining the promise of embryonic stem cells and ways that islets, which are particularly prone to rejection, can be engineered to protect against such an immune response.

• Tolerance, the permanent acceptance of the transplanted graft without the need for drugs, is considered the Holy Grail of transplantation. Results will be presented from innovative trials in the United States and India that suggest the untenable goal is seemingly near. Using different novel methods, the researchers attempted to "expedite" the process and began weaning patients off immunosuppressive drugs just months after transplantation. Teams from the United States, France and Italy also will present results of their studies-- among the few of their kind -- with cohorts of patients off all immunosuppression.

• Not since the world's first hand transplant recipient demanded that surgeons remove the donor graft has the French team discussed the patient's course of chronic rejection at an international scientific forum. The French researchers will present results of the patient's pathology studies as well as a two-year update on the world's first double-hand transplant. Teams from the United States, Italy and China will report on their clinical experience with hand transplantation as well.

• Just when will organs from pigs be ready for transplantation into humans? Several reports have suggested some of the major immunological hurdles have been overcome, and a litter of cloned "knock-out" pigs born about six months ago could bring in the next generation of organ donors. Those active in the field of xenotransplantation, or cross-species transplantation, and cloning will provide an update on where the field stands. Researchers will also report on the promise of cellular xenotransplantation, including one study from the United Kingdom looking at neural stem cells from the developing brain of pigs to treat Parkinson's. Another study from Argentina suggests that pig liver cells might survive and function if transplanted in-utero, representing a potential way to treat liver diseases involving in-born metabolism errors.

• According to one study, an organ preservation system being tested in the United States indicates "marginal" kidneys could indeed be safely transplanted, thus greatly expanding the number of organs available for transplantation. Another experimental device developed in Germany makes use of stem cells isolated from discarded livers to treat patients in acute liver failure until a donor liver can be found. Still, some European transplant centers have found organs from older donors - even those over the age of 80 - to be an effective way to expand the donor pool. Results of these and other studies will be reported.

• Adult stem cells derived from bone marrow may be able to restore function to damaged heart tissue resulting from heart attack, according to a German study using a mouse model.

• Increasingly, organ transplants are being performed in HIV-positive patients with end-stage organ failure. Centers in the United States and Europe will report their results, while one U.S. center will talk about progress developing a gene therapy approach for treating HIV.

• What type of insurance a patient has may contribute to the success of the transplant, according to one study that looked at how various socio-economic factors contributed to transplant success. Results of this U.S. study will be presented.

The preliminary scientific program, press registration and hotel information are available at www.txmiami2002.com. Special hotel rates are available only until July 18. Abstracts will be posted approximately three weeks prior to the congress and embargoed until time and date of presentation, unless otherwise specified. The press room schedule and details of daily highlights will be available at www.txmiami2002.com as soon as they are confirmed and also will be posted on the Web sites for EurekAlert! (www.eurekalert.org) and AlphaGalileo (www.alphagalileo.org). To receive updates and news releases by e-mail or fax, please contact Lisa Rossi at press@txmiami2002.com or 412-624-3184 (fax).

A total of 2,373 abstracts were submitted to the XIX Congress, with 555 (22 percent) accepted as oral presentations and 1,091 abstracts (46 percent) accepted for presentation as posters. An additional 555 abstracts (23 percent) were accepted for publication only in the abstract book. All abstracts will be published in a supplement to the journal Transplantation. In addition, authors of the 200 highest-scoring abstracts will be invited to publish their work as a regular article in a separate issue of Transplantation.

The Transplantation Society was founded in 1966 and serves as the principal international forum for the advancement of both basic and clinical transplantation science. Among its current and former members are six Nobel Laureates. The president of the society is Dr. Carl Groth of the Karolinska Institute in Stockholm. Co-chairs of the congress are Dr. Camillo Ricordi of the Diabetes Research Institute at the University of Miami School of Medicine and Dr. Domingo Casadei of the Instituto de Nefrologia in Buenos Aires.

The International Congress is held every two years. This year's congress had originally been scheduled to take place in Buenos Aires, but due to Argentina's unstable economy, its location was changed earlier this year to the Miami site. The 2004 congress will be held in Vienna.

Transplantation Society

Related Transplantation Articles from Brightsurf:

A revolutionary new treatment alternative to corneal transplantation
A new approach in ophthalmology that offers a revolutionary alternative to corneal transplantation has just been developed by researchers and clinicians in North America, Europe, and Oceania.

Fewer complications after organ transplantation
A large international study coordinated by University Hospital Regensburg and Charité - Universitätsmedizin Berlin has demonstrated the safety of new cell therapy approaches for use in kidney transplant recipients.

Elderly patients also benefit from kidney transplantation
So far, kidney transplantation has generally not been offered to elderly patients (>75 years) because of the perioperative risks.

New material will allow abandoning bone marrow transplantation
Scientists from the National University of Science and Technology 'MISIS' developed nanomaterial, which will be able to restore the internal structure of bones damaged due to osteoporosis and osteomyelitis.

Fewer medical tests -- timely listing for transplantation
Younger patients would benefit greatly from kidney transplantation. Their expected remaining lifetime may even be doubled by having a transplant.

Uterus transplantation -- ethically just as problematic as altruistic surrogacy
In 2014, the first child to have been gestated in a donated uterus was born.

Advancing transplantation: Hepatitis C-infected organs safe for transplantation when followed by antiviral treatment
Twenty patients at Penn Medicine have been cured of the hepatitis C virus (HCV) following lifesaving kidney transplants from deceased donors who were infected with the disease, according to a study published today in Annals of Internal Medicine.

Transplantation followed by antiviral therapy cured hepatitis C
Twenty patients who received kidneys transplanted from hepatitis C virus (HCV)-infected donors experienced HCV cure, good quality of life, and excellent renal function at one year.

The Journal of Heart and Lung Transplantation: 50 years of heart transplantation progress
This month marks the 50th anniversary of the world's first human heart transplant performed at Groote Schuur Hospital in Cape Town by South African surgeon, Christiaan Barnard.

Older donor lungs should be considered for transplantation
With a scarcity of lungs available for transplantation, the use of lungs from donors older than age 60 has been shown to achieve reasonable outcomes and should be considered as a viable option, according to research published online today in The Annals of Thoracic Surgery.

Read More: Transplantation News and Transplantation Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.